Index

Note: Page numbers of article titles are in **boldface** type.

A

Abscess(es)
  liver
    amebic, 276
    pyogenic, 274–275

Acetaminophen
  as biomarker of DILI, 240–241

Acute ascending cholangitis, 216–217

Acute fatty liver of pregnancy (AFLP), 255–257

Adenoma(s)
  hepatic, 278–279

AFLP. See Acute fatty liver of pregnancy (AFLP)

Age
  as risk factor for NAFLD, 400

AH. See Alcoholic hepatitis (AH)

AIC. See Autoimmune cholangiopathy (AIC)

Alagille syndrome, 207

Albumin
  in ascites management, 292–293

Alcohol-related liver disease
  elevated aminotransferases due to, 185, 188
  liver transplantation for, 440

Alcohol use
  deaths related to, 372
  prevalence of, 372

Alcoholic hepatitis (AH), 360–361, **371–385**
  clinical features of, 373–375
  diagnosis of, 372–373
  epidemiology of, 372
  evaluation of
    laboratory values in, 374
    liver biopsy in, 375
    nuclear medicine scan in, 374–375
    patient history in, 373
    physical examination in, 374
  HRS in, 380–381
  introduction, 371
  prognosis in, 375–376
  risk factors for, 372
  treatment of, 376–380
    anti-TNF therapy in, 379
    baclofen in, 379–380
Alcoholic (continued)
  liver transplantation in, 381
  nutrition in, 376–377
  outpatient follow-up, 381
  oxandrolone in, 379
  pentoxifylline, 378–379
  pharmacotherapy in, 378–380
  steroids in, 378
Alkaline phosphate and γ-glutamyltransferase
  elevated
    evaluation of, 190–191
Amebic liver abscess, 276
Aminotransferases
  elevated
    causes of, 185–190
    nonhepatobiliary, 190
    evaluation of, 184–185
  in NAFLD, 400–401
Anemia, 327–328
Anesthesia/anesthetics
  hepatotoxicity due to
    abnormal liver enzymes related to, 193–194
Angiotensin-receptor blockers (ARBs)
  in NAFLD management, 409
Antihistamines
  in pruritus in chronic cholestatic liver disease management, 339
Antioxidants
  in NAFLD management, 408
Anti–tumor necrosis factor (TNF) therapy
  in AH management, 379
ARBs. See Angiotensin-receptor blockers (ARBs)
Ascites, 285–299
  defined, 285
  described, 285
  diagnosis of, 290–291
  formation of
    backward theory of, 285
    overflow theory of, 286
    peripheral arterial vasodilation theory of, 286
  hepatorenal syndrome, 286–289
  nonhepatic, 289–290
  pathophysiology of, 285–286
  refractory, 293
  SBP, 293–295
  tense, 327
  treatment of, 291–293
    albumin in, 292–293
    dietary sodium restriction in, 291
    diuretics in, 292
    nephrotoxic agents in, 291–292
    TIPS in, 291, 293
Autoimmune cholangiopathy (AIC), 208–209
Autoimmune hepatitis
   elevated aminotransferases due to, 189–190
   in pregnancy, 259
Autoimmune liver disease
   liver transplantation for, 442
Autotaxin
   in pruritus of cholestasis, 333–334

B
Baclofen
   in AH management, 379–380
Benign recurrent intrahepatic cholestasis (BRIC), 205, 207
   pruritus in, 341
Bile
   formation of
     physiology of, 200–201
Bile acid(s)
   in pruritus of cholestasis, 332–333
Bile acid sequestrants
   in pruritus in chronic cholestatic liver disease management, 335–336
Biliary disease
   coincident with pregnancy, 261
Biliary strictures
   benign and malignant, 217–218
Biomarker(s)
   in NAFLD diagnosis, 404
Biomarker panels
   in NAFLD diagnosis, 406
Breath
   shortness of. See Shortness of breath
BRIC. See Benign recurrent intrahepatic cholestasis (BRIC)
Brucellosis
   granulomatous liver disease associated with, 391
Budd-Chiari syndrome
   coincident with pregnancy, 261–262

C
CABG. See Coronary artery bypass graft (CABG)
Cancer
   granulomatous liver disease associated with, 392
Chemotherapy
   chronic HBV infection in patients receiving
     treatment of, 360–361
Child-Pugh classification system
   vs. MELD classification system
     in consult for surgical clearance for patient with chronic liver disease, 422–423
Children
   NAFLD in, 399
Cholangiocarcinoma
  liver transplantation for, 444
Cholangiopathy
  autoimmune, 208–209
Cholangitis
  acute ascending, 216–217
  sclerosing
    IgG4-related, 210–212
    primary. See Primary sclerosing cholangitis (PSC)
Choledochal cyst, 217
Choledocholithiasis, 216–217
Cholestasis
  approach to patient with, 199
  benign recurrent intrahepatic
    pruritus in, 341
  defined, 199
  evaluation of, 201–205
    history and physical examination in, 202–204
    laboratory investigation in, 204
    liver test abnormalities in
      pattern of, 201
    management of, 218–219
    progressive familial intrahepatic, 205
    pruritus of
      pathogenesis of, 332–334
      sepsis and, 214
      extrahepatic, 216–218
      genetic disorders of, 205–207
Cholestatic liver disease
  chronic
    pruritus in, 331–346. See also Pruritus, in chronic cholestatic liver disease
    elevated aminotransferases due to, 189–190
    liver transplantation for, 440–442
Chronic cholestatic liver disease
  pruritus in, 331–346. See also Pruritus, in chronic cholestatic liver disease
Chronic HBV infection, 347–369. See also Hepatitis B virus (HBV) infection, chronic
Chronic liver disease
  pulmonary vascular complications of, 323–324
  shortness of breath in, 321–329. See also Shortness of breath, in chronic liver disease
  surgical clearance for patient with, 421–433
    approach to consult for, 421–425
      Child-Pugh vs. MELD classification systems, 422–423
      history and physical examination, 421–422
      liver transplantation status, 423–424
      medical management in perioperative period, 424–425
    surgical risk in patients with
      case examples, 425–430
Cirrhosis
  abdominal surgery in patient with
  surgical risks related to
    case example, 425–427
CABG in patient with
risks related to
case example, 429–430
HCC in patient with
resection of
risks related to
case example, 427–428
in pregnancy, 258–259
primary biliary, 207–208. See also Primary biliary cirrhosis (PBC)
secondary to NAFLD
gastric bypass in
risks related to
case example, 428
Clinical scoring systems
in NAFLD diagnosis, 404–405
Coffee consumption
in NAFLD management, 409
Coronary artery bypass graft (CABG)
in patient with cirrhosis
risks related to
case example, 429–430
Cyst(s)
choledochal, 217
hydatid, 275–276
liver
simple, 272–273
Cystadenoma, 273–274
Cytoprotective agents
in NAFLD management, 408

D
Diabetic medications
in NAFLD management, 408–409
Diabetic NAFLD, 399–400
Dialysis
extracorporeal albumin
in pruritus in chronic cholestatic liver disease management, 336
DILI. See Drug-induced liver injury (DILI)
Disaccharides
nonabsorbable
for ammonia reduction in HE management, 308–310
Diuretics
in ascites management, 292
Drug(s). See also specific types
granulomatous liver disease associated with, 392
hepatotoxicity due to
elevated aminotransferases due to, 188
liver injury due to. See Drug-induced liver injury (DILI)
Drug-induced liver injury (DILI), 215–216, 231–245. See also Hepatotoxicity
biomarker of
acetaminophen, 240–241
Drug-induced (continued)
categories of, 231–245
described, 231
diagnosis of
causality assessment in, 237–241
future prospects for, 242–243
HEV masquerading as, 239–240
management of, 232–234
pathogenesis of, 234–235
prevention of, 235–236
prognosis of, 241
risk factors for, 236–237
treatment of, 241–242
Dubin-Johnson syndrome, 207
Dyspnea. See Shortness of breath

E

Eclampsia
in pregnancy, 253
Encephalopathy
hepatic, 301–320. See also Hepatic encephalopathy (HE)
Endogenous opioids
in pruritus of cholestasis, 333
Enzyme(s)
liver. See Liver enzymes
Ethnicity
as risk factor for NAFLD, 400
Extracorporeal albumin dialysis
in pruritus in chronic cholestatic liver disease management, 336
Extracorporeal liver devices
in HE management, 313
Extrahepatic cholestasis, 216–218

F

Fatigue
in cholestasis
management of, 219
Fatty liver
focal, 277
Fatty sparing, 277
FHF. See Fulminant hepatic failure (FHF)
Fluid analysis
in ascites diagnosis, 290–291
FNH. See Focal nodular hyperplasia (FNH)
Focal fatty liver, 277
Focal nodular hyperplasia (FNH), 277–278
Foreign body(ies)
granulomatous liver disease associated with, 392
Fulminant hepatic failure (FHF)
liver transplantation for, 443
Fungal infections
    granulomatous liver disease associated with, 391

G

Gallstones
    coincident with pregnancy, 261

Gastric bypass
    in patient with cirrhosis secondary to NAFLD
    risks related to
        case example, 428

Gender
    as risk factor for NAFLD, 400

Genetic disorders
    of cholestasis, 205–207

Granulomatous liver disease, 387–396
    associated disease states, 388–393
        brucellosis, 391
        cancer, 392
        chronic HBV infection, 392
        chronic HCV infection, 392
        drugs, 392
        foreign body, 392
        fungal infections, 391
        HIV-related diseases, 391
        idiopathic granulomatous hepatitis, 392
        infectious diseases, 389–392
        lipogranuloma, 392
        MAC, 391
        PBC, 389
        Q fever, 392
        sarcoidosis, 388–389
        schistosomiasis, 392
        tuberculosis, 389–391
    described, 387
    histopathology of, 387–388
    treatment of, 393–394
    consultant in, 393–394

H

HBsAg quantification
    in chronic HBV infection, 356–357

HBV. See Hepatitis B virus (HBV)

HCC. See Hepatocellular carcinoma (HCC)

HCV. See Hepatitis C virus (HCV)

HE. See Hepatic encephalopathy (HE)

HELLP syndrome
    in pregnancy, 253–255

Hemangioma, 276–277

Hepatic adenoma, 278–279
Hepatic encephalopathy (HE), 301–320
  described, 301–302
  diagnosis of, 304–305
  pathophysiology of, 302–304
  treatment of, 305–313
    ammonia reduction in
      nonabsorbable disaccharides in, 308–310
      extracorporeal liver devices in, 313
    neurotransmission modulation in, 311–312
    nutritional deficiencies’ correction in, 312–313
    for precipitating factors, 307–308
    protein restriction in, 312
    rifaximin in, 310–311
Hepatic hydrothorax, 326–327
Hepatic infections, 274
Hepatic sarcoidosis, 212–213
Hepatitis
  alcoholic, 371–385. See also Alcoholic hepatitis (AH)
    autoimmune
      elevated aminotransferases due to, 189–190
      in pregnancy, 259
    idiopathic granulomatous
      granulomatous liver disease associated with, 392
    viral
      coincident with pregnancy, 260–261
      elevated aminotransferases due to, 188–189
      transfusion/transplantation-mediated
        abnormal liver enzymes due to 194
Hepatitis B virus (HBV)
  in pregnancy, 257–258
Hepatitis B virus (HBV) genotype
  in chronic HBV infection, 354–355
Hepatitis B virus (HBV) infection
  chronic, 347–369
    after liver transplantation
      treatment of, 359–360
    geographic predilection for, 347
    HBeAg(+) treatment of, 353
    HBeAg(-) treatment of, 353–354
    HBsAg quantification in, 356–357
    HBV genotype in, 354–355
    IL28B genetic polymorphisms in, 355
    mother-to-child transmission of
      treatment of, 357–359
    in patients receiving chemotherapy or immunosuppressive therapy
      treatment of, 360–361
    prevalence of, 347
    progression of
      viral factors associated with, 354–357
treatment of, 349–354
  antiviral therapy in
    response to, 354–357
    for immune tolerant and inactive carrier phases of infection, 350–353
    in special populations, 357–361
  granulomatous liver disease associated with, 392
  liver transplantation for, 438–439
  phases of, 348–349
Hepatitis C virus (HCV) infection
  granulomatous liver disease associated with, 392
  liver transplantation for, 438
  in pregnancy, 258
Hepatitis E virus (HEV)
  masquerading as DILI, 239–240
Hepatocellular carcinoma (HCC), 279–280
  cirrhosis with
    resection of
      risks related to
        case example, 427–428
      liver transplantation for, 443–444
Hepatopulmonary syndrome
  treatment of, 324
Hepatorenal syndrome (HRS), 286–289
  in AH, 380–381
  described, 286–287
  phases of, 286–288
  treatment of, 288–289
Hepatotoxicity. See also Drug-induced liver injury (DILI)
  anesthetic agent–induced
    abnormal liver enzymes due to, 193–194
  drug-induced
    elevated aminotransferases due to, 188
HEV. See Hepatitis E virus (HEV)
HG. See Hyperemesis gravidarum (HG)
HIV-related diseases
  granulomatous liver disease associated with, 391
HRS. See Hepatorenal syndrome (HRS)
Hydatid cyst, 275–276
Hydrothorax
  hepatic, 326–327
Hyperemesis gravidarum (HG)
  in pregnancy, 250
Hyperferritinemia
  NAFLD and, 401
Hyperlipidemia
  in cholestasis
    management of, 219
Hypertension
  portopulmonary, 324–326
Hyperuricemia
  NAFLD and, 401
ICP. See Intrahepatic cholestasis of pregnancy (ICP)

Idiopathic granulomatous hepatitis

- granulomatous liver disease associated with, 392

IgG4-related sclerosing cholangitis, 210–212

- clinical features of, 211
- described, 210
- diagnosis of, 211–212
- treatment of, 212

IL28B genetic polymorphisms

- in chronic HBV infection, 355

Immunosuppressive therapy

- chronic HBV infection in patients receiving
  - treatment of, 360–361

Incretin mimetics

- in NAFLD management, 409

Infection(s). See also specific types

- hepatic, 274

Infectious diseases

- granulomatous liver disease associated with, 389–392

Inherited/metabolic liver disease

- liver transplantation for, 442

Intrahepatic cholestasis of pregnancy (ICP), 213–214, 250–253

- clinical features of, 214
- defined, 213
- described, 213–214
- diagnosis of, 214
- pruritus in, 340–341
- treatment of, 214

Ischemia

- in postoperative setting
  - abnormal liver enzymes due to, 193

Jaundice

- postoperative
  - abnormal liver enzymes due to, 194

Lesion(s)

- liver
  - evaluation of, 271–283. See also Liver lesions

Lifestyle modification

- in NAFLD management, 406–407

Lipogranuloma

- granulomatous liver disease associated with, 392

Liver

- vascular disease of
elevated aminotransferases due to, 190
liver transplantation for, 443
Liver abscess
amebic, 276
pyogenic, 274–275
Liver disease(s)
alcohol-related
  elevated aminotransferases due to, 185, 188
  liver transplantation for, 440
autoimmune
  liver transplantation for, 442
cholestatic
  chronic
  pruritus in, 331–346. See also Pruritus, in chronic cholestatic liver disease
  elevated aminotransferases due to, 189–190
  liver transplantation for, 440–442
chronic. See Chronic liver disease
  coincident with pregnancy, 260–262
granulomatous, 387–396. See also Granulomatous liver disease
inherited/metabolic
  liver transplantation for, 442
nonalcoholic fatty. See Nonalcoholic fatty liver disease (NAFLD)
  parenteral nutrition–associated, 213
in pregnancy, 247–269. See also Pregnancy, liver diseases in
Liver enzymes
  abnormal
  evaluation of, 191–193
  in postoperative setting
    evaluation of, 193–194
  elevated
    evaluation of, 183–198
      alkaline phosphate and $\gamma$-glutamyltransferase, 190–191
        aminotransferases, 184–185
Liver injury
  drug-induced. See Drug-induced liver injury (DILI)
Liver lesions
  amebic liver abscess, 276
  benign solid, 276–280
    fatty sparing, 277
    FNH, 277–278
    focal fatty liver, 277
    HCC, 279–280
    hemangioma, 276–277
    hepatic adenoma, 278–279
    NRH, 279
  clinical presentation of, 271–272
  cystadenocarcinoma, 273–274
  cystadenoma, 273–274
  described, 271
  evaluation of, 271–283
  hydatid cyst, 275–276
Liver lesions (continued)
- infections, 274
- pyogenic liver abscess, 274–275
- simple cysts, 272–273

Liver transplantation
- in AH management, 381
- benefits of, 437
  candidates for, 435–448
  determination of
    Child-Turcotte-Pugh to MELD score in, 436–437
    evaluation process in, 438
    organ allocation in, 436–437
    severity of illness in, 436–437
  minimal listing criteria for, 437–438
- chronic HBV infection after
  treatment of, 359–360
- contraindications to, 444–446
  absolute, 444–445
  delisting, 446
  relative, 445–446
- historical perspective on, 435–436
  for HRS, 289
- indications for, 438–444
  alcohol-related liver disease, 440
  autoimmune liver disease, 442
  cholangiocarcinoma, 444
  cholestatic liver disease, 440–442
  FHF, 443
  HBV infection, 438–439
  HCC, 443–444
  HCV infection, 438
  inherited/metabolic liver disease, 442
  PBC, 440–442
  vascular disorders of liver, 443
- pregnancy and, 262

Liver transplantation status
- in consult for surgical clearance for patient with chronic liver disease, 423–424

Lyso-phosphatidic acid axis
- in pruritus of cholestasis, 333–334

M

MAC. See Mycobacterium avium-intracellulare complex (MAC)
MELD classification system. See Model for End-Stage Liver Disease (MELD) classification system
Metabolic disorders
- elevated aminotransferases due to, 189
Metformin
- in NAFLD management, 409

Model for End-Stage Liver Disease (MELD) classification system
- vs. Child-Pugh classification system
  in consult for surgical clearance for patient with chronic liver disease, 422–423
Mycobacterium avium-intracellulare complex (MAC)
granulomatous liver disease associated with, 391

N

NAFLD. See Nonalcoholic fatty liver disease (NAFLD)
NASH. See Nonalcoholic steatohepatitis (NASH)

Nephrotoxic agents
in ascites management, 291–292

Nodular regenerative hyperplasia (NRH), 279

Nonalcoholic fatty liver disease (NAFLD), 397–419
aminotransferases in, 400–401
clinical case, 397–398, 410
clinical presentation of, 400
defined, 398
described, 397–398
diabetic, 399–400
diagnosis of, 402–406
biomarker panels in, 406
biomarkers in, 404
clinical case, 406
clinical scoring systems in, 404–405
histology in, 402–403
radiographic modalities in, 403–404
elevated aminotransferases due to, 185
epidemiology of, 398–400
gastric bypass in patient with cirrhosis secondary to
risk related to
case example, 428
hyperferritinemia and, 401
hyperuricemia and, 401
laboratory abnormalities in, 400–401
management of, 406–410
adjunct weight loss pharmacotherapy in, 407
antioxidants in, 408
ARBs in, 409
coffee consumption in, 409
cytoprotective agents in, 408
diabetic medications in, 408–409
incretin mimetics in, 409
lifestyle modification in, 406–407
metformin in, 409
omega 3 fatty acid supplementation in, 409
surgical, 407
TZDs in, 408–409
UDCA in, 408
natural history of, 401–402
pediatric, 399
prevalence of, 399
risk factors for, 400
vitamin D deficiency and, 401
Nonalcoholic steatohepatitis (NASH)
  defined, 398
  described, 398
  prevalence of, 399
Nonhepatic ascites, 289–290
NRH. See Nodular regenerative hyperplasia (NRH)
Nutrition
  in AH management, 376–377
  parenteral
    liver disease associated with, 213
Nutritional deficiencies
  in HE
    correction of, 312–313
O
Obesity
  prevalence of, 399
Omega 3 fatty acid supplementation
  in NAFLD management, 409
Opioid(s)
  endogenous
    in pruritus of cholestasis, 333
Opioid antagonists
  in pruritus in chronic cholestatic liver disease management, 337–338
Osteoporosis
  in cholestasis
    management of, 219
Oxandrolone
  in AH management, 379
P
Paracentesis
  in ascites diagnosis, 290
Parenteral nutrition
  liver disease associated with, 213
PBC. See Primary biliary cirrhosis (PBC)
Pentoxifylline
  in AH management, 378–379
Peripheral arterial vasodilation theory
  of arterial formation, 286
Peritonitis
  spontaneous bacterial, 293–295. See also Spontaneous bacterial peritonitis (SBP)
PFIC. See Progressive familial intrahepatic cholestasis (PFIC)
Plasmapheresis
  in pruritus in chronic cholestatic liver disease management, 336
Portopulmonary hypertension, 324–326
Preeclampsia
  in pregnancy, 253
Pregnancy
  intrahepatic cholestasis of, 213–214, 250–253. See also Intrahepatic cholestasis of pregnancy (ICP)
liver diseases coincident with, 260–262
  biliary disease, 261
  Budd-Chiari syndrome, 261–262
  gallstones, 261
  viral hepatitis, 260–261
liver diseases in, 247–269
  AFLP, 255–257
  eclampsia, 253
  HELLP syndrome, 253–255
  HG, 250
  ICP, 250–253
  preeclampsia, 253
  preexisting underlying, 257–260
    autoimmune hepatitis, 259
    cirrhosis, 258–259
    HBV, 257–258
    HCV, 258
    PBC, 259–260
    PSC, 259–260
    Wilson disease, 260
  liver physiology during, 247–249
  liver transplantation and, 262
  modality of testing in, 249
Primary biliary cirrhosis (PBC), 207–208
  clinical features of, 207
  described, 207
  diagnosis of, 207
  granulomatous liver disease associated with, 389
  liver transplantation for, 440–442
  in pregnancy, 259–260
  treatment of, 208
Primary sclerosing cholangitis (PSC), 209–210
  clinical features of, 209–210
  described, 209
  diagnosis of, 210
  in pregnancy, 259–260
  treatment of, 210
Progressive familial intrahepatic cholestasis (PFIC), 205
Protein restriction
  in HE management, 312
Pruritus
  in BRIC, 341
  of cholestasis
    management of, 218–219
    pathogenesis of, 332–334
  in chronic cholestatic liver disease, 331–346
    described, 331
    management of, 334–340
      agents modulating threshold of nociception in, 339
      algorithm for, 339–340
      antihistamines in, 339
Pruritus (continued)
- bile acid sequestrants in, 335–336
- extracorporeal albumin dialysis in, 336
- interventions directed at removal of presumed pruritogens, 335–336
- interventions directed at underlying conditions, 334–335
- interventions to alter metabolism of presumed pruritogens, 337
- interventions to modify central and/or peripheral pruritus pathways, 337–339
- opioid antagonists in, 337–338
- plasmapheresis in, 336
- serotonin modulators in, 338–339
  - manifestation of, 332
  - natural history of, 332
  - pathogenesis of, 332–334
  - in special populations, 340–341
  - described, 331
  - in ICP, 340–341
  - in special cholestasis populations, 340–341
PSC. See Primary sclerosing cholangitis (PSC)
Pyogenic liver abscess, 274–275

Q
Q fever
  - granulomatous liver disease associated with, 392

R
Radiography
  - in NAFLD diagnosis, 403–404
Refractory ascites, 293
Renal replacement therapy
  - for HRS, 289
Rifaximin
  - in HE management, 310–311

S
Sarcoidosis
  - granulomatous liver disease associated with, 388–389
  - hepatic, 212–213
SBP. See Spontaneous bacterial peritonitis (SBP)
Schistosomiasis
  - granulomatous liver disease associated with, 392
Sclerosing cholangitis
  - IgG4-related, 210–212. See also IgG4-related sclerosing cholangitis
  - primary. See Primary sclerosing cholangitis (PSC)
Sepsis
  - cholestasis related to, 214
Serotonin
  - in pruritus of cholestasis, 333
Serotonin modulators
  - in pruritus in chronic cholestatic liver disease management, 338–339
Serum alkaline phosphatase elevated
  approach to patient with, 199–229. See also Cholestasis, evaluation of
case example, 199–200
  outcome in, 219

Shortness of breath
  in chronic liver disease, 321–329
  anemia, 327–328
differential diagnosis of, 321–322
evaluation of
  laboratory tests in, 322–323
  physical examination in, 322
  hepatic hydrothorax, 326–327
  hepatopulmonary syndrome, 324
  portopulmonary hypertension, 324–326
tense ascites, 327

Sodium restriction
  in ascites management, 291

Spontaneous bacterial peritonitis (SBP), 293–295
  described, 293
  prevalence of, 293
  prevention of, 294–295
  treatment of, 294

Steatohepatitis
  nonalcoholic
    defined, 398
    described, 398
    prevalence of, 399

Steroids
  in AH management, 378

T

Tense ascites, 327
TIPS. See Transjugular intrahepatic portosystemic shunting (TIPS)
TNF. See Tumor necrosis factor (TNF)
Transjugular intrahepatic portosystemic shunting (TIPS)
  in ascites management, 291, 293

Transplantation
  liver. See Liver transplantation

Tuberculosis
  granulomatous liver disease associated with, 389–391

TZDs
  in NAFLD management, 408–409

U

UDCA
  in NAFLD management, 408
Vascular disease of liver
   elevated aminotransferases due to, 190
   liver transplantation for, 443
Viral hepatitis
   coincident with pregnancy, 260–261
   elevated aminotransferases due to, 188–189
   transfusion/transplantation-mediated
   abnormal liver enzymes due to, 194
Vitamin deficiencies
   D
      NAFLD and, 401
   fat-soluble
      in cholestasis
      management of, 219

Weight loss
   medications for
      in NAFLD management, 407
   surgical therapy for
      in NAFLD management, 407
Wilson disease
   in pregnancy, 260